Cliff Asness's ATRC Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 186,382 shares of AtriCure, Inc. (ATRC) worth $5.32 M, representing 0.00% of the portfolio. First purchased in 2014-Q1, this long-term strategic position has been held for 46 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in ATRC, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2026, adding 86,426 shares. Largest reduction occurred in Q2 2025, reducing 15,972 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's AtriCure (ATRC) Holding Value Over Time
Track share changes against reported price movement
Quarterly AtriCure (ATRC) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +86,426 | Add 86.46% | 186,382 | $28.53 |
| Q4 2025 | +15,784 | Add 18.75% | 99,956 | $39.56 |
| Q3 2025 | +16,459 | Add 24.31% | 84,172 | $35.25 |
| Q2 2025 | -15,972 | Reduce 19.09% | 67,713 | $32.77 |
| Q1 2025 | +837 | Add 1.01% | 83,685 | $32.26 |
| Q4 2024 | +7,531 | Add 10.00% | 82,848 | $30.56 |
| Q3 2024 | +16,579 | Add 28.23% | 75,317 | $28.04 |
| Q2 2024 | +16,251 | Add 38.25% | 58,738 | $22.77 |
| Q1 2024 | +29,217 | Add 220.17% | 42,487 | $30.42 |
| Q4 2023 | +3,221 | Add 32.05% | 13,270 | $35.69 |
| Q3 2023 | +4,586 | Add 83.95% | 10,049 | $43.80 |
| Q2 2023 | +323 | Add 6.28% | 5,463 | $49.36 |
| Q1 2023 | -1,272 | Reduce 19.84% | 5,140 | $41.45 |
| Q4 2022 | -2,085 | Reduce 24.54% | 6,412 | $44.38 |
| Q3 2022 | -206 | Reduce 2.37% | 8,497 | $39.07 |
| Q2 2022 | -5,219 | Reduce 37.49% | 8,703 | $40.91 |
| Q1 2022 | +1,908 | Add 15.88% | 13,922 | $65.65 |
| Q4 2021 | -22 | Reduce 0.18% | 12,014 | $69.50 |
| Q3 2021 | +1,621 | Add 15.56% | 12,036 | $69.54 |
| Q2 2021 | -769 | Reduce 6.88% | 10,415 | $79.31 |
| Q1 2021 | -7,828 | Reduce 41.17% | 11,184 | $65.54 |
| Q4 2020 | -2,571 | Reduce 11.91% | 19,012 | $55.65 |
| Q3 2020 | +5,900 | Add 37.62% | 21,583 | $39.89 |
| Q2 2020 | +15,683 | New Buy | 15,683 | $44.95 |
| Q4 2019 | -12,900 | Sold Out | 0 | $0.00 |
| Q3 2019 | -4,187 | Reduce 24.50% | 12,900 | $24.96 |
| Q2 2019 | -59 | Reduce 0.34% | 17,087 | $29.85 |
| Q1 2019 | +2,252 | Add 15.12% | 17,146 | $26.77 |
| Q4 2018 | -6,371 | Reduce 29.96% | 14,894 | $30.62 |
| Q3 2018 | -1,705 | Reduce 7.42% | 21,265 | $35.03 |
| Q2 2018 | +10,727 | Add 87.62% | 22,970 | $27.04 |
| Q4 2017 | +581 | Add 4.98% | 12,243 | $18.21 |
| Q3 2017 | +11,662 | New Buy | 11,662 | $22.38 |
| Q4 2016 | -10,047 | Sold Out | 0 | $0.00 |
| Q2 2016 | -4,932 | Reduce 32.93% | 10,047 | $14.13 |
| Q1 2016 | -3,029 | Reduce 16.82% | 14,979 | $16.82 |
| Q4 2015 | -3,192 | Reduce 15.06% | 18,008 | $22.43 |
| Q3 2015 | -3,745 | Reduce 15.01% | 21,200 | $21.89 |
| Q2 2015 | +4,745 | Add 23.49% | 24,945 | $24.65 |
| Q1 2015 | -15,800 | Reduce 43.89% | 20,200 | $20.50 |
| Q4 2014 | -9,300 | Reduce 20.53% | 36,000 | $19.97 |
| Q3 2014 | +2,500 | Add 5.84% | 45,300 | $14.72 |
| Q2 2014 | +13,000 | Add 43.62% | 42,800 | $18.39 |
| Q1 2014 | +29,800 | New Buy | 29,800 | $18.83 |
Cliff Asness's AtriCure Investment FAQs
Cliff Asness first purchased AtriCure, Inc. (ATRC) in Q1 2014, acquiring 29,800 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held AtriCure, Inc. (ATRC) for 46 quarters since Q1 2014.
Cliff Asness's largest addition to AtriCure, Inc. (ATRC) was in Q1 2026, adding 186,382 shares worth $5.32 M.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 186,382 shares of AtriCure, Inc. (ATRC), valued at approximately $5.32 M.
As of the Q1 2026 filing, AtriCure, Inc. (ATRC) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in AtriCure, Inc. (ATRC) was 186,382 shares, as reported at the end of Q1 2026.